念珠菌.pdfVIP

I D S A G U I D E L I N E S Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America Peter G. Pappas,1 Carol A. Kauffman,2 David Andes,4 Daniel K. Benjamin, Jr.,5 Thierry F. Calandra,11 John E. Edwards, Jr.,6 Scott G. Filler,6 John F. Fisher,7 Bart-Jan Kullberg,12 Luis Ostrosky-Zeichner,8 Annette C. Reboli,9 John H. Rex,13 Thomas J. Walsh,10 and Jack D. Sobel3 1University of Alabama at Birmingham, Birmingham; 2University of Michigan and Ann Arbor Veterans Administration Health Care System, Ann Arbor, and 3Wayne State University, Detroit, Michigan; 4 University of Wisconsin, Madison; 5Duke University Medical Center, Durham, North Carolina; 6Harbor–University of California at Los Angeles Medical Center, Torrance; 7 Medical College of Georgia, Augusta; 8University of Texas at Houston, Houston; 9Cooper Hospital, Camden, New Jersey; 10National Cancer Institute, Bethesda, Maryland; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Nijmegen University Centre for Infectious Diseases, Nijmegen, The Netherlands; and 13Astra Zeneca Pharmaceuticals, Manchester, United Kingdom Guidelines for the management of patients with invasive candidiasis and mucosal candidiasis were prepared by an Expert Panel of the Infectious Diseases Society of America. These updated guidelines replace the previous guidelines published in the 15 January 2004 issue of Clinical Infectious Diseases and are intended for use by health care providers who care for patients who either have or are at risk of these infections. Since 2004, several new antifungal agents have become available, and se